首页> 外文OA文献 >Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study

【2h】

Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study

机译：每14天的多西紫杉醇和环磷酰胺的可行性每14天作为乳腺癌的佐剂方案：威斯康星州肿瘤学网络研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Mark E. Burkard; Kari B. Wisinski; Uchenna O. Njiaju; SarahMaria Donohue; Robert Hegeman; Amy Stella; Patrick Mansky; Varsha Shah; Timothy Goggins; Rubina Qamar; Leah Dietrich; KyungMann Kim; Anne M. Traynor; Amye J. Tevaarwerk;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. 老年乳腺癌术后多西紫杉醇联合环磷酰胺辅助化疗的毒副作用研究 [J] . Lingqin Song, Yinbin Zhang, Jianjun He, 中德临床肿瘤学杂志（英文版） . 2011,第007期
2. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A wisconsin oncology network study [J] . BurkardM.E., WisinskiK.B., NjiajuU.O., Clinical breast cancer . 2014,第3期

机译：每14天进行4周期多西紫杉醇和环磷酰胺作为乳腺癌辅助治疗方案的可行性：威斯康星州肿瘤学网络研究
3. Feasibility of 4 cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A wisconsin oncology network study [J] . BurkardM.E., WisinskiK.B., NjiajuU.O., Clinical breast cancer . 2014,第3期

机译：每14天的多西紫杉醇和环磷酰胺的可行性每14天作为乳腺癌的佐剂方案：威斯康星州肿瘤学网络研究
4. Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. [J] . Drullinsky P, Sugarman SM, Fornier MN, Clinical breast cancer . 2010,第6期

机译：剂量密集的环磷酰胺，甲氨蝶呤，氟尿嘧啶每隔14天可行一次：每14天给药一次作为乳腺癌辅助治疗的初步研究。
5. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
6. Boron Neutron Capture Therapy for HER2+ breast cancers: A feasibility study evaluating BNCT for potential role in breast conservation therapies. [D] . Jenkins, Peter Anthony. 2012

机译：HER2 +乳腺癌的硼中子捕获疗法：评估BNCT在乳腺癌保护疗法中潜在作用的可行性研究。
7. Feasibility of four cycles of docetaxel and cyclophosphamide every 14 days as an adjuvant regimen for breast cancer: A Wisconsin Oncology Network Study [O] . Mark E. Burkard, Kari B. Wisinski, Uchenna O. Njiaju, -1

机译：每14天进行四轮多西紫杉醇和环磷酰胺作为乳腺癌辅助治疗方案的可行性：威斯康星州肿瘤网络研究
8. FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG) [O] . Polyzos, Aristides, Malamos, Nikolaos, Boukovinas, Ioannis, 2009

机译：FEC与序贯多西紫杉醇联合表柔比星/环磷酰胺作为腋窝淋巴结阳性早期乳腺癌妇女的辅助化疗：古希腊肿瘤研究组（HORG）的一项随机研究

Feasibility of 4 Cycles of Docetaxel and Cyclophosphamide Every 14 Days as an Adjuvant Regimen for Breast Cancer: A Wisconsin Oncology Network Study

著录项

引文网络

相似文献

相关主题

期刊订阅